- Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studiesDavid Madigan
Department of Statistics, Columbia University, 1255 Amsterdam Avenue, New York, NY 10027, USA
Am Heart J 164:186-93. 2012..We studied contemporaneously adjudicated CVT events to assess the information on cardiovascular risk available while the drug was in widespread use...
- Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillanceJoseph S Ross
Department of Geriatrics and Palliative Medicine, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1070, New York, NY 10029, USA
Arch Intern Med 169:1976-85. 2009....